726 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Catalyst Capital Advisors LLC

Catalyst Capital Advisors LLC purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 726 shares of the medical research company’s stock, valued at approximately $54,000.

A number of other large investors have also added to or reduced their stakes in the stock. AlphaCentric Advisors LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $691,000. Baillie Gifford & Co. grew its position in Edwards Lifesciences by 238.7% during the fourth quarter. Baillie Gifford & Co. now owns 706,796 shares of the medical research company’s stock worth $52,324,000 after buying an additional 498,100 shares in the last quarter. Sierra Ocean LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $98,000. J.W. Cole Advisors Inc. acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $259,000. Finally, Seascape Capital Management grew its position in Edwards Lifesciences by 3.9% during the fourth quarter. Seascape Capital Management now owns 34,262 shares of the medical research company’s stock worth $2,536,000 after buying an additional 1,273 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $75.67 on Wednesday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $72.78 and a two-hundred day moving average price of $69.68. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a market cap of $44.63 billion, a P/E ratio of 10.92, a PEG ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Barclays upped their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Truist Financial restated a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $79.95.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,555,402. The trade was a 12.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 26,489 shares of company stock worth $2,002,829. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.